LDN for Graves' Disease: What the Evidence Really Shows

Low dose naltrexone (LDN) for Graves' disease has no direct clinical evidence. As of October 2026 there are no randomized trials, no registered trials on ClinicalTrials.gov, and no PubMed-indexed case reports of LDN in Graves' hyperthyroidism or thyroid eye disease. The rationale is extrapolated: small trials in fibromyalgia (Younger et al., 2013), immune marker studies in multiple sclerosis (Ludwig et al., 2017), mixed results in Crohn's disease, and clinician anecdotes from functional medicine practices. LDN at 1.5 to 4.5 mg does not lower thyroid hormone output, so it cannot stand in for methimazole. This guide grades the evidence, explains the specific risks in a hyperthyroid patient, and lays out how to monitor if you and your endocrinologist decide to try it.

If you came here from our Hashimoto's LDN guide, the picture is different in important ways. Hashimoto's destroys the thyroid. Graves' overdrives it. The same drug sits next to very different medicines and carries different stakes.

Why Graves' Patients Ask About LDN

Graves' disease is driven by thyrotropin receptor antibodies (TRAb). These antibodies switch on the TSH receptor and keep the gland producing hormone around the clock. Standard care follows the 2016 American Thyroid Association guidelines (Ross et al., 2016) and the 2018 European Thyroid Association guideline (Kahaly et al., 2018): methimazole for 12 to 18 months as the usual first choice, then a check of TRAb before stopping. Radioactive iodine and thyroidectomy are the definitive options.

Many patients want something that addresses the immune side directly. Methimazole blocks hormone production; it does not target the antibody-making cells. Relapse after a course of antithyroid drugs is common, and nobody enjoys the idea of losing the gland to iodine or surgery. LDN has a reputation as a gentle immune modulator in autoimmune circles, so the question is natural.

The online answers are thin. The top results for "ldn for graves disease" are podcasts, forum threads and pharmacy pages. A 2013 forum moderator at the Graves' Disease and Thyroid Foundation noted the absence of credible Graves'-specific research. Some functional medicine clinicians describe using it in Graves' patients, but those reports are unpublished and untracked. An endocrinologist answering on theMednet, a physician Q&A platform, states plainly that they do not prescribe it for thyroid disease because they have not found data to support it.

That is the honest starting point.

What LDN Is

Naltrexone is an opioid receptor blocker, approved by the FDA at 50 mg for alcohol and opioid dependence. "Low dose" means roughly a tenth of that, typically 1.5 to 4.5 mg taken at night. At these doses it is used off-label, almost always from a compounding pharmacy. The broader background, history and prescription process are covered in our complete LDN guide. This article stays on Graves'.

How LDN Might Work in Graves' Disease

Two mechanisms dominate the LDN literature. A third, regulatory T cell support, comes up constantly in patient forums. Each has a real basis and a real gap.

The TLR4 and innate immune hypothesis

Toll-like receptor 4 (TLR4) sits on microglia, macrophages and other innate immune cells. When it fires, those cells release inflammatory cytokines. Hutchinson et al. (2008, European Journal of Neuroscience) showed that naloxone and (+)-naltrexone block TLR4 signaling in cell lines and reverse neuropathic pain in rats.

There is a catch that most LDN marketing skips. The naltrexone in your prescription is the (-) form, which binds opioid receptors. The cleanest TLR4 data come from the (+) form. When Cant et al. (2017, Frontiers in Immunology) tested naltrexone on human blood immune cells, it did not change cytokine output after TLR4 stimulation. It did reduce IL-6 and TNF-alpha after stimulation of TLR7, TLR8 and TLR9, intracellular receptors linked to B cells and plasmacytoid dendritic cells.

That B cell detail is interesting for Graves', since TRAb is made by B cells. It remains a test-tube finding.

The opioid growth factor (OGF) axis

The second mechanism belongs to Zagon and McLaughlin's group at Penn State. A brief nightly blockade of opioid receptors is thought to trigger a rebound rise in the body's own [Met5]-enkephalin, also called opioid growth factor. OGF acting on its receptor slows the proliferation of rapidly dividing cells, including activated lymphocytes.

Ludwig et al. (2017, Experimental Biology and Medicine) found serum [Met5]-enkephalin was lower in people with multiple sclerosis than in neurology patients without MS, and LDN restored it. In mice with experimental autoimmune encephalomyelitis, Hammer et al. (2016) reported that injected OGF reduced CD4 T cells in the central nervous system, while LDN did not, and neither changed the T helper cell profile.

So the OGF story has human biomarker support in MS and partial support in mice. No one has measured enkephalin levels in Graves'.

What about regulatory T cells?

Graves' patients often read that LDN "boosts Tregs," the T cells that keep autoimmunity in check. We could not find a peer-reviewed human study showing that LDN raises regulatory T cell numbers or function. The claim usually traces back to the OGF animal work or to general reviews. Treat it as a hypothesis.

Cytokine data from fibromyalgia

The best human immune data come from Jarred Younger's lab. In an 8-week single-blind study of 8 women with fibromyalgia, Parkitny and Younger (2017, Biomedicines) reported lower plasma levels of many cytokines, including IL-6, IL-17A and TNF-alpha, alongside a 15% drop in pain. That is a pilot. It also involves a disease with no autoantibody at its center.

What the Evidence Actually Shows for Graves' Disease

We searched PubMed for naltrexone combined with Graves', hyperthyroidism and orbitopathy. The searches returned nothing on LDN as a treatment for Graves' disease or thyroid eye disease. ClinicalTrials.gov lists no registered study of naltrexone in Graves'. Any article that cites "studies" of LDN in Graves' is citing studies of something else.

Here is what exists nearby, and what it tells you.

Hashimoto's, the closest relative. There are no randomized trials there either. A Norwegian prescription registry study of 898 patients with hypothyroidism (Raknes and Småbrekke, 2020, BMC Endocrine Disorders) found no reduction in levothyroxine or T3 use in the year after starting LDN. If anything, levothyroxine use trended slightly upward with more LDN exposure. A 2022 review in the Journal of Clinical Endocrinology and Metabolism (Larsen et al.) concluded that LDN has little to no evidence of impact on thyroid disorders.

Crohn's disease, the most studied autoimmune use. A Cochrane review (Parker et al., 2018) found only two small trials with 46 participants and rated the evidence low quality. One adult trial showed better clinical and endoscopic response with LDN. Then, in September 2026, a Dutch multicenter trial (van de Pol et al., Digestive Diseases and Sciences) was stopped early for futility: 41 patients, endoscopic remission 5.6% on LDN versus 18.8% on placebo, clinical remission 22.2% versus 70.0% (placebo significantly better, p = 0.037). Fatigue scores did improve on LDN; other patient-reported outcomes did not differ.

Fibromyalgia. Younger et al. (2013, Arthritis and Rheumatism) ran a crossover trial in 31 women: pain fell 28.8% on LDN versus 18.0% on placebo. Life satisfaction and mood improved. Fatigue and sleep did not.

The pattern across conditions is consistent. LDN seems more reliable for how people feel (pain, fatigue, mood) than for hard disease markers. That is worth knowing before you hope it will lower your TRAb.

Evidence grades for Graves'-specific questions

LDN in Graves' vs Hashimoto's: The Key Differences

Most LDN-for-thyroid content is written for Hashimoto's and then stretched to cover Graves'. The two diseases sit on opposite sides of the thyroid, and the practical safety questions change with them.

LDN does not replace antithyroid drugs

In Hashimoto's, a person on LDN still takes levothyroxine. Missing a dose of either is not dangerous in the short term. In Graves', the antithyroid drug is what stands between you and uncontrolled thyrotoxicosis: rapid heart rate, atrial fibrillation, bone loss, weight loss, anxiety, and at the extreme, thyroid storm. LDN has no effect on hormone synthesis. It cannot take methimazole's job.

The full picture of Graves' care, including which supplements to avoid and why iodine is dangerous, is in our Graves' disease natural treatment guide.

The thyroid swing question

In Hashimoto's, the theoretical risk is that LDN calms the immune attack, the gland recovers a little, and the patient becomes over-replaced on a fixed levothyroxine dose. In Graves', the mirror image would apply: if LDN genuinely lowered TRAb, a fixed methimazole dose could push you toward hypothyroidism.

This is reasoning, not observation. And it is hard to separate from what methimazole does on its own. TRAb usually falls during a course of antithyroid drugs, and the dose often needs to come down over time. Any downward drift in thyroid levels after starting LDN is far more likely to be methimazole doing its job. The fix is the same either way: check labs and let your endocrinologist adjust the antithyroid dose.

Beta blockers and overlapping symptoms

Many Graves' patients take propranolol, atenolol or metoprolol early on to control heart rate and tremor. We found no known pharmacological interaction between naltrexone and beta blockers. The problem is overlap. LDN's most common side effects are insomnia and vivid dreams in the first weeks. Propranolol can disturb sleep and cause vivid dreams too. Hyperthyroidism itself causes insomnia, anxiety and palpitations.

Starting LDN while thyroid levels are still settling makes every new symptom ambiguous. That argues for waiting until your thyroid function is stable on antithyroid treatment before adding anything new.

Interactions and Safety Notes

Opioids. This is the one hard interaction. LDN blocks opioid receptors, so opioid pain medicines (including tramadol and codeine) may not work, and taking LDN while dependent on opioids can trigger withdrawal. LDN is usually paused several days before planned surgery. Tell every surgeon and anesthetist you take it.

Methimazole and PTU. No known direct interaction with LDN. Both antithyroid drugs carry warnings for liver injury and agranulocytosis (a dangerous drop in white blood cells). Naltrexone at full 50 mg doses once carried a boxed liver warning; the FDA removed the box in 2013, though a hepatotoxicity precaution remains in the full label. At 1.5 to 4.5 mg, liver effects are not a recognized concern, but if your liver enzymes are already being watched for methimazole, keep that schedule.

Selenium, vitamin D and L-carnitine. No known interaction. These are covered with their own grades in the Graves' natural treatment guide and our vitamin D and thyroid guide.

Immune-stimulating supplements. Ashwagandha can raise thyroid hormone levels and is a poor fit for Graves'. See our ashwagandha and thyroid review before combining anything with LDN.

Pregnancy. Graves' in pregnancy is managed with careful drug switching (PTU in the first trimester, per ETA 2018). LDN data in pregnancy are limited. Do not start it during pregnancy or while trying to conceive without specialist input.

LDN Dosing as Used in Practice

No dose has been studied in Graves' disease. Prescribers who use it borrow the protocol used across autoimmune conditions. Discuss every step with your doctor.

LDN is compounded as capsules or liquid. Fillers matter to some patients; ask the pharmacy about lactose and dyes. Prescription routes are covered in the main LDN guide.

Timing LDN within a Graves' treatment course

There are three common situations, and LDN fits them differently.

Newly diagnosed, thyroid still high. Wait. Get thyroid levels under control first. Adding LDN now creates symptom confusion and offers nothing for the urgent problem.

Stable on methimazole, months 3 to 18. This is the window where an add-on trial makes the most sense, if it makes sense at all. Thyroid levels are predictable, side effects are easier to read, and you have scheduled labs anyway.

Relapsed after a course, considering definitive treatment. LDN is sometimes raised as a way to avoid radioactive iodine or surgery. There is no evidence that it improves remission odds. The 2018 ETA guideline lists continued long-term low-dose methimazole as an option for people who relapse and want to keep their gland, which is a better-supported path to discuss.

How to Monitor LDN with Graves' Disease

The point of monitoring is to separate three things: what methimazole is doing, what the disease is doing, and what LDN might be doing. The schedule below layers on top of the antithyroid drug monitoring your endocrinologist already does.

Which markers matter

TRAb or TSI. This is the disease marker. The ETA guideline recommends measuring it at diagnosis, before stopping antithyroid drugs, and in pregnancy. A persistently high TRAb at 12 to 18 months suggests continuing methimazole rather than stopping. For a broader explanation of thyroid antibody tests, see our thyroid antibodies guide.

Free T4 and Free T3. These tell you how much hormone is circulating right now. Some Graves' patients run a T3-predominant pattern, so Free T3 matters more than it does in Hashimoto's.

TSH. Useful later, but TSH can stay suppressed for months after hormone levels normalize. Early in treatment it lags behind reality.

Symptoms and heart rate. A resting pulse log and a simple sleep score give you a baseline to compare against when LDN starts.

Setting a fair test

Before starting, agree with your doctor on what would count as a result. A reasonable bar: a meaningful improvement in fatigue or pain within three months at maintenance dose, without a change in antithyroid needs that cannot be explained. If you see no difference, stopping is a valid result, not a failure.

Be careful with TRAb. Because it tends to fall on methimazole alone, a decline after starting LDN proves nothing. Without a comparison group, you cannot credit LDN for it.

LDN and Thyroid Eye Disease

A substantial share of Graves' patients develop some degree of thyroid eye disease (TED), also called Graves' orbitopathy. Estimates range from roughly 25 to 50 percent depending on the population and how closely the eyes are examined, and most cases are mild. Eye pain, grittiness, bulging, and double vision are the common signs. There are no published studies of LDN in TED. This is an area where established treatments exist and delay can cost vision.

Mild, active TED. Selenium has randomized evidence. Marcocci et al. (2011, New England Journal of Medicine) randomized 159 patients with mild Graves' orbitopathy to selenium (100 mcg twice daily), pentoxifylline or placebo for six months. Selenium improved quality of life, reduced eye involvement and slowed progression; pentoxifylline did not. The 2021 EUGOGO guidelines (Bartalena et al., European Journal of Endocrinology) recommend selenium for mild active disease in selenium-deficient areas. Grade B for mild TED: one large RCT plus guideline endorsement. Our selenium guide covers forms and safe upper limits.

Moderate to severe, active TED. EUGOGO 2021 recommends IV methylprednisolone combined with mycophenolate as first-line in Europe, with teprotumumab among the second-line options. In the United States, the IGF-1 receptor blocker teprotumumab (Tepezza) has been the standard biologic since its 2020 approval. In the phase 3 OPTIC trial (Douglas et al., 2020, NEJM), 83% of patients on teprotumumab had a proptosis response at 24 weeks, versus 10% on placebo. Grade A.

A second IGF-1R drug. On June 26, 2026, the FDA approved veligrotug (Lumvoa, Viridian Therapeutics) for TED regardless of disease activity or duration, given as five IV infusions every 3 weeks. Approval rested on two placebo-controlled phase 3 trials, THRIVE (active TED, published in Ophthalmology in 2026) and THRIVE-2 (chronic TED). Like teprotumumab, its label carries warnings about hearing impairment, high blood sugar and inflammatory bowel disease flares.

Smoking. The strongest modifiable risk factor for TED, named first in the EUGOGO guideline's list of risks alongside high TRAb and radioactive iodine treatment.

LDN has no role here until someone studies it. If your eyes are changing, see an ophthalmologist or oculoplastic specialist familiar with TED.

When LDN Should Not Be Tried

LDN is well tolerated in trials, but "safe drug" and "right drug" are different questions. Skip it, or wait, in these situations:

• Thyroid levels not yet controlled. Fix the hyperthyroidism first.
• Any opioid use, including tramadol, codeine or opioid maintenance therapy, or surgery planned within the next few weeks.
• Active moderate to severe eye disease that has not been assessed by a specialist.
• Pregnancy or trying to conceive, unless a specialist is involved.
• As a reason to delay radioactive iodine, surgery or long-term methimazole that your endocrinologist recommends.
• Recent atrial fibrillation or heart failure linked to thyroid excess, until a cardiologist has weighed in.
• Severe liver disease, where any added medication deserves extra caution.

Where LDN Might Reasonably Fit

For a stable Graves' patient on methimazole with persistent fatigue, pain or a coexisting condition where LDN has some data (fibromyalgia, long COVID fatigue), a time-limited trial with clear stopping rules is a defensible conversation to have with a doctor. If your Graves' started or flared after a COVID infection, our LDN for long COVID guide covers that evidence. Stress is a well-known trigger for Graves' relapse; practical approaches are in our stress and thyroid guide.

For lowering TRAb, raising remission odds or treating eye disease, LDN is not the tool. Better-supported options exist for each, and they are listed in the Graves' natural treatment guide and our supplement evidence review.

Frequently Asked Questions

Does LDN work for Graves' disease?

Nobody knows. There are no randomized trials, no case series and no PubMed-indexed case reports of LDN in Graves'. The rationale comes from fibromyalgia, multiple sclerosis and Crohn's research plus clinician anecdote. Grade C at best. Any benefit is most plausible for fatigue or pain, not for TRAb or hormone levels.

Can LDN replace methimazole?

No. Methimazole blocks thyroid hormone production. LDN does not. Untreated hyperthyroidism risks atrial fibrillation, bone loss and thyroid storm. LDN, if used, goes alongside antithyroid treatment.

What LDN dose is used for Graves'?

The general autoimmune schedule: start at 0.5 to 1.5 mg at bedtime, titrate to 1.5 to 4.5 mg. No dose has been tested in Graves'. Discuss titration with your doctor and report insomnia or palpitations.

Is LDN safe with propranolol or methimazole?

There is no known direct interaction. The issue is overlapping side effects, especially sleep disruption. Methimazole's liver and blood count monitoring continues unchanged. The firm interaction is with opioids.

Can LDN help thyroid eye disease?

No study has tested it. Selenium has Grade B evidence (one large RCT, guideline-endorsed) for mild TED. Teprotumumab has Grade A evidence for moderate to severe TED, and the newly approved veligrotug (Lumvoa) was approved on two positive phase 3 trials. See a specialist for any new eye symptoms.

How do I know if LDN is working with Graves'?

Agree on a goal before you start, ideally a symptom target such as fatigue or pain. Track Free T4, Free T3 and TSH at 4 to 6 weeks and TRAb at 6 months. A falling TRAb is expected on methimazole alone, so it cannot be credited to LDN by itself.

Find Your Personalized Protocol

Graves' disease, Hashimoto's and other autoimmune conditions call for different priorities, and the right add-ons depend on your labs, medications and symptoms. Take the free 3-minute quiz to see which evidence-graded interventions fit your situation.

This site provides educational information only. Not medical advice. Always consult your healthcare provider before changing your treatment plan. Never stop or reduce methimazole, PTU or beta blockers without medical supervision. LDN is used off-label and has not been studied in Graves' disease.